The recombinant antibodies are identical to traditional
monoclonal antibodies in their basic functionality. They
can be manufactured using fully in-vitro processes, thus,
offering greater fl exibility during their production and
greater opportunities for optimization after their creation
than typical monoclonal antibodies, as these kinds of technologies
also facilitate production, screening and maturation
of selected binders, allowing selection on target conformations
and formats which are not possible by more
traditional routes based on immunization. The easy availability
of the gene sequence not only provides a defi nitive
description of the product but also allows electronic sharing
and recreation of the binding molecule through gene
synthesis.